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Background: Aberrant biometal metabolism is a key feature of neurodegenerative disorders including Alzheimer’s
and Parkinson’s diseases. Metal modulating compounds are promising therapeutics for neurodegeneration, but
their mechanism of action remains poorly understood. Neuronal ceroid lipofuscinoses (NCLs), caused by mutations
in CLN genes, are fatal childhood neurodegenerative lysosomal storage diseases without a cure. We previously
showed biometal accumulation in ovine and murine models of the CLN6 variant NCL, but the mechanism is
unknown. This study extended the concept that alteration of biometal functions is involved in pathology in these
disorders, and investigated molecular mechanisms underlying impaired biometal trafficking in CLN6 disease.
Results: We observed significant region-specific biometal accumulation and deregulation of metal trafficking pathways
prior to disease onset in CLN6 affected sheep. Substantial progressive loss of the ER/Golgi-resident Zn transporter, Zip7,
which colocalized with the disease-associated protein, CLN6, may contribute to the subcellular deregulation of biometal
homeostasis in NCLs. Importantly, the metal-complex, ZnII(atsm), induced Zip7 upregulation, promoted Zn redistribution
and restored Zn-dependent functions in primary mouse Cln6 deficient neurons and astrocytes.
Conclusions: This study demonstrates the central role of the metal transporter, Zip7, in the aberrant biometal
metabolism of CLN6 variants of NCL and further highlights the key contribution of deregulated biometal trafficking to the
pathology of neurodegenerative diseases. Importantly, our results suggest that ZnII(atsm) may be a candidate for
therapeutic trials for NCLs.
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Biometals including Zn and Cu are immensely important
for brain function. When homeostatic control fails in aging
or disease, biometal mislocalization or altered homeostasis
can drive pathological changes as observed in patients
suffering from neurodegenerative diseases [1], as the
brain is especially vulnerable to metal-induced oxidative* Correspondence: arwhite@unimelb.edu.au
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unless otherwise stated.stress. Importantly, even subtle changes to biometal
concentrations have been associated with significant
neuronal pathology [2].
Neuronal ceroid lipofuscinoses (NCLs), commonly
known as Batten diseases, are a genetically heteroge-
neous group of lysosomal storage diseases (LSDs) [3],
characterized by storage of lipofuscin material in
lysosome-derived fluorescent storage bodies [4,5] and
neuronal demise leading to progressive loss of vision,
motor dysfunction and premature death [6]. Oxidative
stress and neuroinflammation phenotypes in NCLs are
reminiscent of other forms of neurodegeneration. Al-
ternative mutations in the metal transporter ATP13a2ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nism, suggesting a common pathway [7-11], however the
functions of the NCL proteins and underlying disease
processes are not well understood. A variant late infant-
ile and an adult onset NCL are caused by mutations in
CLN6, which encodes a highly conserved transmem-
brane endoplasmic reticulum (ER) protein of unknown
function [12,13].
We previously demonstrated region-specific alterations
to biometal homeostasis in ovine CLN6 disease that cor-
related with the development of neurodegeneration [14].
Moreover, biometal accumulation was associated with
region-specific loss of Cln6 mRNA in presymptomatic
Cln6 affected mice [15]. However, the mechanisms re-
sponsible for these changes remain unknown. Here we
show that altered biometal trafficking pathways involve
loss of ER-co-localized transmembrane proteins, CLN6
and the metal transporter Zip7, triggering subcellular
metal accumulation in presymptomatic CLN6 disease.
Moreover, correction of impaired metal-dependent func-
tions in Cln6 cells is achieved via up-regulation of Zip7 by
a cell permeable metal complex, ZnII(atsm). These studies
demonstrate the potential of biometal modulation for the
development of therapeutics for CLN6 disease.
Materials and methods
Sheep
The CLN6 Merino and South Hampshire research flocks
were maintained under standard pasture conditions on
University research farms and genotyped as described
[16]. As previously reported, Merino CLN6 sheep are
phenotypically normal until the age of 8–12 months [17].
From approximately 8 months, the affected sheep exhibit
mild behavioural changes and visual impairment, which
progress throughout disease course, resulting in prema-
ture death between 19 to 27 months of age [17]. Similar to
the South Hampshire CLN6 model, the affected Merino
sheep brains do not develop normally to maturity and
begin to atrophy from approximately 6 months of age.
The genotype of Merino sheep was determined by geno-
typing for the disease causing c.184C > T mutation in the
CLN6 gene [18]. Homozygous normal animals were used
as controls. CLN6 South Hampshire sheep were used as
an additional model of CLN6 disease. For comparison to
affected CLN6 South Hampshire sheep, we used un-
affected homozygous controls. As an additional control
group, we used unaffected heterozygous CLN5 Borderdale
sheep, as previously described [19]. All animal procedures
were carried out according to NIH guidelines, the NSW
Animal Research Act (1985), the New Zealand Animal
Welfare Act (1999), and the Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes
7th Edition (NHMRC 2004). Brain and peripheral samples
were collected from 3, 7 and 14 month-old control andCLN6 affected Merino sheep, 12–14 month-old control
and CLN6 affected South Hampshire sheep and un-
affected CLN5 heterozygote Borderdale sheep. At post
mortem, brains were dissected into the following re-
gions: occipital lobe, parietal lobe, frontal lobe, thal-
amus, cerebellum and brain stem, and immediately
frozen. Liver and muscle (rectus femoris) tissue was also
collected for analysis.
Mice
Animal handling and experimentation were performed
in accordance with national and institutional guidelines
(University of Melbourne AEC no. 1112024). The geno-
types of affected Cln6 mice [20] (B6.Cg-Cln6nclf/J, The
Jackson Laboratory) were determined as previously de-
scribed [15]. Mice were euthanized by CO2 asphyxiation
or cervical dislocation, as appropriate.
Cell culture
Primary cortical neuronal cultures were established from
embryonic day 14 (E14) mice, and primary astrocytes were
harvested from neonatal mice as previously described
[21]. For primary cortical cultures, E14 mouse cortices
were removed, dissected free of meninges and dissociated
in 0.025% trypsin. Viable dissociated cells were suspended
in Minimum Eagle’s Medium supplemented with 10% fetal
bovine serum (FBS), 5% horse serum, 1% glutamine, and
10 μg/mL gentamicin, plated into Poly-D-lysine coated
culture plates, and incubated at 37°C in 5% CO2. Growth
medium was replaced with Neurobasal growth medium
supplemented with B27, glutamine and gentamicin the
following day. 3–4 days after plating, half of the media
was replaced with fresh Neurobasal media. Cells were
used for experiments 6 days after plating.
For astrocyte culture, newborn mice were decapitated,
the brains removed and placed into ice-cold preparation
buffer (containing 68 mM NaCl, 2.7 mM KCl, 110 μM
KH2PO4, 84.5 μM Na2HPO4, 29 mM sucrose, 2.8 mM
glucose, 20U/mL penicillin and 34.4pM streptomycin).
Brains were diced, then sequentially passed through
250 μm and 135 μm gauze and centrifuged at 500×g for
5 min. Cell pellets were resuspended in growth medium
(high glucose DMEM containing 10% FCS, 20U/mL peni-
cillin and 34.4pM streptomycin) and plated into 6 well
plates at 1.5×106 cells/well. Cells were maintained at 37°C
with 10% CO2. Growth medium was replaced every 7 days,
and experiments were performed after 16 days in vitro.
ZnII(atsm) was added to cells cultured in Neurobasal
medium for neurons or high glucose DMEM (Life
Technologies) containing 10% FCS, 20 U/mL penicillin
and 34.3pM streptomycin for astrocytes. High content
screening analysis was used to visualize and quantitate
neurite characteristics of primary neurons, as described in
supplementary methods.
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The metal contents in sheep occipital, parietal and frontal
lobes, cerebellum, thalamus, brainstem, liver and muscle
were measured using inductively coupled plasma mass-
spectrometry (ICP-MS) as before [14].
Cathepsin D assay
Cathepsin D activity was measured using a Fluorometric
cathepsin D activity assay kit (Abcam, Cambridge, MA).
Alkaline phosphatase (ALP) assay
ALP activity assays were performed on primary mouse
astrocytes, as described [22], p-nitrophenol release be-
ing measured at 405 nm over 30 min using shrimp
ALP (Sigma-Aldrich, Castle Hill, NSW, Australia) as a
standard.
FluoZin-3 fluorescence
Mouse neurons were pre-treated with 5 μM FluoZin-3 (Life
Technologies) for 30 min, followed by a 30 min washout.
Fluorescence was measured with an Enspire plate reader
(PerkinElmer, Glen Waverley, Victoria, Australia) in well
scan mode at excitation and emission wavelengths of 494
and 516 nm, respectively.
High content screening analysis
Primary cortical mouse neurons plated in clear bottom
Costar 96 well plates (Corning, Tewksbury, MA) were
treated with ZnII(atsm) [23] for 1 h, at the concentrations
indicated. Cells were fixed for 15 min in 4% PFA in phos-
phate buffered saline (PBS), permeabilised for 10 min at
−20°C with ice-cold 100% methanol, and blocked with
5% FCS and 0.03% Triton-X100 in PBS. Zip7 complexes
were detected with rabbit α-Zip7 (1:500; ProteinTech,
Chicago, IL) in dilution buffer (1% BSA, 0.03% Triton-
X100 in PBS) and goat-α-rabbit IgG AlexaFluor 647
(1:500, Life Technologies). Cell nuclei were stained with
DAPI (1.5 μM, Life Technologies). For the measurement
of neurite lengths, cellular tubulin was stained with rabbit
α-tubulin antibodies (1:50; Cell Signaling, Arundel,
Queensland, Australia). Staining in cells was viewed
with a Cellomics ArrayScan VTI HCS Reader (Thermo
Scientific, Scoresby, Victoria, Australia). The Cellomics
ArrayScan VTI HCS Reader is a high throughput
microscopy-based screening analysis platform, which pro-
vides highly reproducible quantitative and qualitative data
that can be obtained from cell populations in 96 well plate
format. Due to rapid data acquisition, the ability to meas-
ure 1000s of cells per treatment condition and lack of ex-
perimenter bias, the Cellomics technology is now well
accepted for routine use in neurite outgrowth assays, as evi-
denced by a number of highly cited publications [24-26]. At
least 1,000 cells or 20 fields per well were captured with
the 20× objective. Data were analyzed with vHCS 116Discovery Toolbox software (Thermo Scientific), using
the compartmental analysis or neuronal profiling bioap-
plications, as appropriate (Additional file 1). For analysis
of Zip7 staining intensity, the nucleus was identified by
DAPI staining using the vHCS 116 Discovery Toolbox
software. The perinuclear region of each cell was desig-
nated as beginning 2 μm from the perimeter of the
nucleus, and extending for a 2 μm radius around the
nucleus. The average pixel intensity of this region was
calculated and plotted for at least 1000 cells per well,
performed in triplicate wells. The experiment was re-
peated 4 times with similar results.
Immunofluorescent staining
Immunofluorescent staining was performed as previously
described [27]. Briefly, primary cortical mouse neurons
were seeded onto coverslips in 24 well plates, treated with
ZnII(atsm) for 4 h, fixed in 4% PFA, permeabilised in 0.1%
Triton-X100 in PBS, and blocked in 5% FCS in PBS. Zip7
was detected using polyclonal rabbit-α-Zip7 antibodies
(1:500), and goat-α-rabbit AlexaFluor 488 (1:500; Life
Technologies). Cell nuclei were visualized with DAPI.
Coverslips were mounted onto microscope slides with
fluorescence mounting media (DAKO, Campbellfield,
Victoria, Australia) and visualized with a Leica DMIRB
fluorescence microscope. For colocalization studies,
primary mouse cortical neurons were reacted with
rabbit primary anti-CLN6 and goat primary anti-Zip7
antibodies. Anti-goat AlexaFluor-488 and anti-rabbit
AlexaFluor-568 dye labeled secondary antibodies were
used to reveal Zip7 and CLN6 expression, respect-
ively. ER localization was determined by staining with
the rabbit polyclonal antibodies to the ER marker, cal-
nexin (1:100; Abcam) and anti-rabbit AlexaFluor-568
dye labeled secondary antibodies. Fluorescence was
visualized by confocal microscopy using the Zeiss
Meta confocal scanning laser microscope with a mag-
nification of 40x.
qRT-PCR
RNA was prepared from 106 primary mouse neuronal
cells using the MagMax Total RNA isolation kit (Life
Technologies). RNA (200 ng) was reverse transcribed
using the High Capacity cDNA kit (Life Technolo-
gies). TaqMan gene expression assays for MT1A and
TUBA8 were purchased from Life Technologies
(Mm00496660_g1 and Mm00833707_mH, respectively)
and qRT-PCR was performed as previously described [15].
Delta Ct method was used for normalization of expression
relative to β-tubulin.
siRNA transfection
Mouse NIH 3T3 cells (6×105/mm2) were cultured for
24 h in DMEM supplemented with 10% FBS, 1% 20 U/mL
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HEPES and 1% non essential amino acids. Transfection
was achieved with DharmaFECT transfection reagent 4
(Thermo Scientific) and 100 nM Stealth Select RNAi siRNA
specific to Zip7 (oligo ID MSS205001) or Negative control
High GC siRNA (both from Life Technologies) according
to manufacturer specifications. siRNA-transfection reagent
complexes were incubated for 20 min in DMEM prior to
dropwise addition to cells. Cell media was changed after
24 h to DMEM containing 10% FBS. 72 h after transfection,
cells were harvested for Western blotting by scraping and
centrifugation (18,000×g, 5 min).
Western blotting
Cell lysates and tissues homogenized with a Dounce tissue
grinder were extracted with Phosphosafe (Merck, Kilsyth,
Victoria, Australia) containing a protease inhibitor cocktail
(Roche, Castle Hill, NSW, Australia) and DNAse (Roche).
The protein concentrations of supernatants after centrifu-
gation (12,000×g, 5 min, 4°C) were measured with the BCA
assay kit (Pierce) according to manufacturer’s instructions.
Equal protein amounts were separated on 12% SDS-PAGE
Tris-glycine or 4-12% Bis-Tris gels (Life Technologies), as
appropriate. Proteins were transferred to PVDF membranes
and blocked with 4% skim milk solution in PBS-Tween.
Membranes were probed overnight with primary antibodies
diluted in 4% skim milk solution in PBS-Tween. Unless
stated otherwise, primary antibodies were raised in rabbits
and were diluted 1:1000. The antibodies used in this study
were directed against: CLN6 (kindly provided by Dr. Sara
Mole, University College London), mouse Zip3 (Abnova),
Zip7 (1:2000, Proteintech), Zip8 (1:1200, Proteintech),
Zip14 (Novus), ZnT1 (Sigma), ZnT3 (Proteintech), ZnT6
(1:1200, Proteintech), ZnT7 (Proteintech), mouse α-
synuclein (1:2000, kindly provided by Professor Malcolm
Horne, The Florey Institute of Neurosciences), V-ATPase
(GenScript), as well as the phosphorylated form of
GSK-3 (Cell Signaling Technologies). The horseradish
peroxidase-conjugated anti-mouse or anti-rabbit second-
ary antibodies (Cell Signaling Technologies) were used at a
dilution of 1:5000. Membranes were developed by chemilu-
minescence (Amersham ECL Advance Western blotting
detection kit) and imaged on a Fujifilm LAS3000 Imager
(Berthold). Western blots were subjected to densitometry
analysis using ImageJ software.
Target band intensities were compared to control bands
(ImageJ, Bethesda, MD) on blots probed with antibodies
against GAPDH, β-tubulin, total Akt or total ERK used as
controls to normalize protein concentrations in CLN6 af-
fected and control animals.
Statistical analyses
Differences in metal content, gene expression, protein
concentrations, ALP activities and neurite characteristicswere determined using unpaired Student’s t-tests. p values
below 0.05 were considered significant. Data are expressed
as means ± SEM and are representative of a minimum of
three independent experiments. Where sheep data are pre-
sented, N = three or four animals per group. Pearson cor-
relation coefficients were used to determine the strength
of correlation between Zn, P-GSK, metallothionein, CLN6
and Zip7 levels in individual sheep.
Results
Impaired lysosomal function and neurodegeneration-
associated proteinopathy in NCLs
Lysosomal dysfunction, prior to the onset of clinical
signs in CLN6 affected Merino sheep, which occurs at
8–12 months [17], was demonstrated by reduced cathep-
sin D activity from 3 months of age (Figure 1A). An age-
dependent reduction of subunit B2 of V-ATPase was
also observed in the occipital lobe, the site of initial
neuropathological changes of South Hampshire CLN6
sheep (Figure 1B) [28], suggestive of defects in lysosomal
functionality [29]. Due to the close relationship between
NCLs and Parkinson’s disease, we examined the levels of
Parkinson’s disease proteins, α-synuclein, and the metal
transporter, ATP13a2. Significantly increased concentra-
tions of the high molecular weight form of α-synuclein
[30] and a trend toward increased ATP13a2 levels (p =
0.1782) were also observed after onset of neurological
disease (Figure 1C-D), providing further support for a
relationship between Parkinson’s and NCL diseases.
Biometals accumulate in preclinical CLN6 sheep
We previously reported accumulation of Zn, Mn, Co
and Cu in disease-affected brain regions of CLN6
Merino and South Hampshire sheep after the onset of
clinical signs [14]. To investigate biometal changes in early
NCL pathology, we determined metal concentrations in
3 and 7 month old normal and affected Merino sheep
(Table 1). Zn concentrations were higher in the parietal
lobe and muscle of affected sheep at 7 months of age,
but lower in the liver of 3 month-old and plasma of
7 month-old affected sheep. Liver Mn concentrations
were substantially reduced, and plasma Co reduced at
3 and 7 months of age (Additional file 2). Cu concen-
trations in the occipital and frontal lobes were higher
in affected animals at both ages while those in the par-
ietal lobe, brainstem and cerebellum where higher than
control values at 3 months but lower at 7 months. In-
creased Cu concentrations were also observed in the
liver of 3 and 7 month old CLN6 sheep. Together, these
data indicate that disturbances to biometal homeostasis
may precede detectable clinical signs in CLN6 disease.
Moreover, biometal alterations not only occur in the cen-
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Figure 1 Lysosomal dysfunction and increased α-synuclein concentrations in CLN6 sheep. (A) Cathepsin D activity was measured in
homogenates (1 μg) isolated from the occipital lobe of 3, 7 and 14 month old control or CLN6 affected Merino sheep (N = 3 per group) using a
fluorometric Cathepsin D activity assay. (B-D) Densitometry and representative immunoblots of homogenates (5–40 μg) isolated from the
occipital lobe of 3, 7 and 14 month old control or CLN6 affected sheep probed with antibodies directed against V-ATPase (B), α-synuclein (C) or
ATP13a2 (D). GAPDH was used as a loading control. Quantification was performed in ImageJ and concentrations are expressed relative to those
in control sheep at each age. Data are mean + SEM. **p < 0.01, ***p < 0.001 by Student’s t test. C, control.
Table 1 Increased biometal concentrations in the brain of
preclinical CLN6 Merino sheep
Zna Cua
Age Control CLN6 Control CLN6
Frontal
3 11.1 ± 0.2 11.1 ± 0.7 2.0 ± 0.2 2.3 ± 0.2*
7 11.4 ± 0.2 12.1 ± 1.4 2.2 ± 0.3 2.7 ± 0.6
Occipital
3 11.2 ± 0.4 11.2 ± 1.2 2.2 ± 0.5 2.8 ± 0.3*
7 13.1 ± 0.5 13.9 ± 1.9 2.5 ± 0.2 3.4 ± 0.9*
Parietal
3 10.7 ± 0.9 11.0 ± 0.4 1.8 ± 0.3 2.5 ± 0.1^
7 12.9 ± 0.6 13.6 ± 0.4* 2.5 ± 0.4 2.1 ± 0.3
Thalamus
3 10.7 ± 1.3 10.5 ± 0.6 2.1 ± 0.4 1.8 ± 0.1
7 10.6 ± 1.0 11.6 ± 1.3 2.7 ± 1.2 2.7 ± 1.3
Cerebellum
3 12.2 ± 1.1 12.5 ± 1.3 2.8 ± 0.4 3.0 ± 0.5
7 11.4 ± 0.5 11.6 ± 0.5 3.4 ± 0.5 2.3 ± 0.4^
Brainstem
3 11.2 ± 1.0 11.7 ± 0.6 2.5 ± 0.3 2.8 ± 0.3*
7 8.52 ± 0.8 9.2 ± 0.4 1.9 ± 0.2 1.5 ± 0.4
Liver
3 53.9 ± 18.5 36.3 ± 9.2* 20.2 ± 2.6 37.1 ± 1.6#
7 28.1 ± 5.3 29.5 ± 3.0 40.4 ± 7.7 58.2 ± 6.5#
Muscle
3 22.0 ± 4.5 21.5 ± 1.9 0.6 ± 0.4 0.5 ± 0.2
7 19.9 ± 3.0 27.3 ± 4.1^ 0.2 ± 0.1 0.3 ± 0.2
Plasma
3 11.7 ± 1.1 12.0 ± 2.1 13.6 ± 2.0 14.3 ± 2.7
7 14.0 ± 1.4 10.5 ± 1.8* 12.8 ± 1.1 10.2 ± 2.2
aMetal concentrations in the CNS and peripheral tissues of 3 and 7 month old
control and CLN6 Merino sheep were measured using ICP-MS. The concentrations
of Zn and Cu in each tissue are expressed as mean ± S.D. Values correspond to
μg metal/g tissue. *p < 0.05, ^p < 0.01, #p < 0.001 by Student’s t test.
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pathways are associated with loss of CLN6
Western blotting revealed an age related decline in the
relative amount of CLN6 in the affected occipital lobe,
resulting in very low levels at 14 months (Figure 2A).
We assessed the expression levels of the Cu transporters,
CTR1, ATP7A, ATP7B, but observed no differences in
expression of these proteins between control and CLN6
Merino sheep (unpublished data). We next focused on
Zip and ZnT metal transporter proteins, initially identi-
fied for Zn transport and reported to transport different
subsets of the biometals altered in CLN6 affected sheep
[31-35]. The ER/Golgi-resident transporter, Zip7, was pro-
gressively lost in the affected occipital lobe in an age-
dependent manner from 3 months, reaching statistical sig-
nificance from 7 months (Figure 2B, full blot of Zip7
shown in Additional file 3). Significantly reduced expres-
sion of Zip8, Zip14 and ZnT7 in affected Merino sheep
was apparent by 14 months of age (Figure 2C-E), whereas
ZnT1, ZnT3 and ZnT6 concentrations were relatively
unchanged (Additional file 4). Similar alterations to the
concentrations of metal trafficking proteins were also
observed in 12 month-old CLN6 affected South Hamp-
shire sheep, except that ZnT6 expression was reduced,
while ZnT7 expression was unaffected in this model (Add-
itional file 5). The Zn and Cu sequestering protein, me-
tallothionein (MT), was upregulated ~40 fold in
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Figure 2 Altered biometal trafficking pathways are associated with loss of CLN6 in sheep. (A-F) Densitometry and representative
immunoblots of homogenates (5–40 μg) isolated from the occipital lobe of 3, 7 and 14 month old control or CLN6 affected sheep (N = 3 per
group) probed with antibodies directed against CLN6 or a range of metal transporters or metal binding proteins. GAPDH, β-tubulin, total Akt or
total ERK, as appropriate, were used as loading controls. Quantification was performed in ImageJ and levels are expressed relative to those in
control sheep at each age. Data are mean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test. C, control. (G-H) Normalized Zip7 protein
levels in Merino sheep occipital lobe were plotted against normalized levels of CLN6 (G) or MT (H) to determine correlations between these
proteins. Linear regression analysis was performed in GraphPad Prism.
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as reported [14]. Correlation analysis revealed a strong
positive relationship between the levels of Zip7 and
CLN6 and a strong negative correlation between Zip7
and MT levels in individual sheep (Figure 2G-H).
In addition to the occipital lobe, a significant decrease in
Zip7 occurred in the frontal and parietal lobes of CLN6
affected Merino sheep by 14 months of age (Additional
file 6). Significant reductions were also observed in thecerebellum and thalamus of similarly aged CLN6 af-
fected South Hampshire sheep (Additional file 7B-C),
indicating that reduction of Zip7 occurs throughout the
brain in both breeds of sheep.
Brain Zn is aberrantly elevated in sucrose density gradient
fractions corresponding to the ER and Golgi in Cln6 mouse
brains [15]. We therefore investigated whether deregulation
of subcellular biometal homeostasis also occurred in CLN6
sheep. To investigate early changes, before substantial
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occipital lobes from 3-month old control and CLN6 af-
fected Merino sheep (Figure 3). Subcellular distribu-
tion profiles of Zn and Cu were significantly altered,
with increased Zn and Cu in the lighter fractions (frac-
tions 1–7) of CLN6 affected brains (Figure 3A-B).
Interestingly, Zip7 is lost in these fractions in CLN6 af-
fected brains (Figure 3C), consistent with retention of
excess metals in those fractions in CLN6 animals. We
also probed fractions for CLN6, but were unable to de-
tect CLN6 protein in any fraction (unpublished data).
Cln6 neurons display defects in Cln6 transcription and
perinuclear Zip7 staining
Given the challenges of in vitro studies in sheep, we further
investigated the role of Zip7 in CLN6 disease using mice
carrying a natural mutation in Cln6 [20]. Cln6 mRNA
expression (Figure 4A) and perinuclear Zip7 staining
(Figure 4B,D) were significantly reduced in neurons
cultured from Cln6 mutant mice. To investigate whether
reduced Zip7 expression was associated with elevated
labile Zn content, we used a cell-permeable Zn-binding
fluorophore, FluoZin-3, which senses Zn that is not tightly
protein-bound (Kd = 15 nM). Consistent with a defect in
Zip7-mediated trafficking, readily exchangeable Zn pools
were substantially increased in neurons harvested from
































Figure 3 Biometals accumulate in subcellular fractions that
display Zip7 loss in presymptomatic CLN6 sheep occipital lobe.
Sucrose density gradient fractions from 3 month old sheep occipital
lobe were analyzed for metal content by ICP-MS. Data are expressed as
the mean + SEM of Zn (A) and Cu (B) concentrations in CLN6 brains
(white bars throughout) and control brains (black bars throughout) from
3 individual sheep per genotype. (C) Representative immunoblot of Zip7
protein present in fractions from control and CLN6 affected sheep brains.ER-localized transmembrane Zip7 and CLN6 [13,36], as-
sociate was explored through confocal immunofluores-
cence. Cortical neurons were co-labeled with antibodies
to Zip7 (Figure 5B) and CLN6 (Figure 5C). Perinuclear
and punctate staining was observed throughout the cell
body and neurites, suggestive of ER/Golgi localization.
Importantly, a degree of colocalization between CLN6
and Zip7 was observed (Figure 5D), indicating that
these proteins may associate in punctate structures
throughout the cell. Co-localization of Zip7 with the ER
marker, calnexin, verified that Zip7 was at least partially
ER-localized (Additional file 8). These results indicate
that loss of Zip7 is detectable in mice prior to birth, and
provide support for an association between Zip7 and
CLN6 disease.
Delivery of bioavailable Zn restores Zn-dependent
phenotypes through upregulation of Zip7
Therapeutic modulation of biometal homeostasis has
demonstrated promise in the treatment of neurodegen-
erative disorders [37-39]. Although bulk analysis sug-
gested overall metal accumulation in CLN6 disease, loss
of the ER to cytoplasmic metal importer, Zip7, would
ultimately drive metal mislocalization to the ER, as pre-
viously observed for Zn in Cln6 mutant mouse brain
[15], and may induce deficiencies of bioavailable metals
elsewhere in the cell. Membrane-permeable complexes
that deliver bioavailable metals may therefore bypass the
Zip7 defects in Cln6 cells. In light of this, Zn was deliv-
ered using the cell-permeable metallo-complex ZnII
(atsm) [40]. ZnII(atsm) treatment significantly decreased
the readily exchangeable Zn pool in primary Cln6 neu-
rons, as measured by FluoZin-3 fluorescence (Figure 6A).
The apparent paradox of delivering Zn but observing re-
duced FluoZin-3 fluorescence is likely to occur via ZnII
(atsm)-dependent upregulation of MT (Figure 6B), and
therefore sequestration of excess labile Zn [41]. The re-
sults support abnormal compartmental Zn levels in Cln6
affected cells due to Zip7 loss and the ability of ZnII
(atsm) to at least partially rectify this by up-regulation of
MT. As increased labile Zn can trigger neurite outgrowth
[42], we next examined the neurite characteristics of Cln6
neurons. Indeed, Cln6 cells displayed longer, more ex-
tensively branched neurites, which were retracted upon
1 h treatment with up to 5 μM ZnII(atsm) (Figure 6C,
Additional file 1). Together, these data suggest that ZnII
(atsm) restores metal homeostasis in Cln6 primary
neurons.
Although it is neurons that degenerate in NCL disease,
astrocytes are severely affected prior to disease onset in
both sheep and mouse NCL models [43,44]. We there-
fore also examined a range of Zn-dependent activities in
primary astrocytic cultures. We measured the activity of






























































Figure 4 Cln6 cortical neurons display reduced Cln6 transcripts
and Zip7 staining with increased labile Zn accumulation. (A)
Cln6 mRNA expression in primary murine cortical neurons was
measured using qRT-PCR. Expression values were normalized to
tubulin using the delta Ct method. All data are mean + SEM. (B) Zip7
expression was assessed by immunofluorescence. Zip7 was
labeled with rabbit Zip7 antibodies and AlexaFluor conjugated
anti-rabbit antibodies. Nuclei were stained with DAPI. Quantitative
analysis of Zip7 perinuclear distribution was performed using the
ArrayScan reader in conjunction with the compartmental analysis
software on >1000 cells per genotype. (C) Labile Zn in control and
Cln6 cortical neurons was measured by FluoZin-3 fluorescence. (D)
Zip7 immunofluorescence images are representative of 3 experi-
ments performed on triplicate coverslips. Scale bars represent 10 μm.
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activity [45]. Reduced ALP activity in Cln6 astrocytes
was indicative of regional Zn depletion, but was restored
by 1 μM ZnII(atsm) treatment (Figure 6D). Elevated la-
bile Zn can result in aberrant GSK3 phosphorylation
[46], evident in CLN6 sheep [14] and primary Cln6
mouse astrocytes (Figure 6E). ZnII(atsm)-dependent res-
cue of hyperphosphorylated GSK-3 in Cln6 astrocytes
was associated with increased Zip7 (Figure 6E) demon-
strating a link between Zn, GSK3 and Zip7 expression.
Together the data suggest complex deregulation of sub-
cellular Zn pools in Cln6 cells - increased labile Zn in
specific sub-cellular regions and reduced bioavailable Zn
in alternative compartments required for enzyme func-
tions. Importantly, our data show a strong in vitro pro-
tective effect of ZnII(atsm) on Zn mislocalization caused
by Cln6 mutation. Interestingly, Zip7 levels in individual
sheep were inversely correlated to levels of P-GSK3 and
Zn (Figure 6F-G), supporting functional or regulatory
relationships between these proteins and cellular Zn
concentrations. Consistent with a role for Zip7 in this
process, siRNA knockdown of Zip7 in mouse NIH 3T3 cells
resulted in hyperphosphorylation of GSK3 (Figure 6H-J).
These data provide further support for a role of Zip7
in homeostatic control of a kinase that is deregulated in
neurodegeneration.
Discussion
We demonstrated that CLN6 loss is associated with sig-
nificant biometal accumulation in the brains of CLN6
affected Merino sheep prior to onset of clinical signs.
We observed deregulated metal transporters belonging
to the Zip and ZnT families in affected brain regions
(Figure 2B-E). Zip7 was the earliest transporter altered,
with loss of expression in sucrose density fractions from
3 month-old CLN6 sheep (Figure 3) and in perinatal
mouse Cln6 cells (Figure 4B,D). Zip7 was thus the only
transporter with altered expression in multiple CLN6
disease models [15], and the only ER-localized metal trans-





Figure 5 Zip7 co-localizes with CLN6. Primary mouse cortical neurons were reacted with rabbit primary anti-CLN6 and goat primary anti-Zip7
antibodies. Anti-goat AlexaFluor-488 and anti-rabbit AlexaFluor-568 dye labeled secondary antibodies were used to reveal Zip7 and CLN6 expression,
respectively. (A) DAPI, (B) Zip7 and (C) CLN6 expression in primary cortical neurons was visualized by confocal microscopy using the Zeiss Meta
confocal scanning laser microscope using a magnification of 40×. (D) Overlay images indicate colocalization in punctate structures throughout the
cells. Scale bars correspond to 20 μm.
Grubman et al. Acta Neuropathologica Communications 2014, 2:25 Page 9 of 14
http://www.actaneurocomms.org/content/2/1/25directly affected by loss of CLN6. Indeed, CLN6 co-
localized with Zip7 in murine cortical neurons (Figure 5)
and reduced Zip7 expression occurred concomitantly with
elevated labile Zn in primary Cln6 neurons (Figure 4C).
This study implicates Zip7 as a potentially important con-
tributor to NCLs.
Stringent regulation of biometal homeostasis by cellular
trafficking systems is critical to prevent metal-induced
toxicity. Mn overexposure causes Parkinsonism and α-
synuclein accumulation [47]. The latter was observed in
CLN6 affected sheep (Figure 1B), occurs in another
LSD, Gaucher’s disease [48], and was recently associated
with lysosomal dysfunction in a rare genetic form of
parkinsonism, Kufor-Rakeb syndrome, caused by muta-
tions in ATP13a2 [49]. Indeed, mutations, altered ex-
pression or aberrant functionality of metal transporters
belonging to the ATP7, ATP13, TRMPL and ZnT fam-
ilies has been implicated in neurodegenerative disorders
with pathological or clinical similarities to NCLs, and in
the LSDs, Niemann-Pick C and Mucolipidosis [50-56].
As increased ATP13a2 expression was reported torescue lysosomal dysfunction in Parkinson’s disease fibro-
blasts [57], we hypothesise that upregulation of ATP13a2
in CLN6 affected sheep may similarly compensate to par-
tially improve lysosomal function. Together, these studies
emphasize that while the precise mechanisms underlying
altered metal homeostasis in neurodegeneration are spe-
cific for each disease, neurodegenerative processes invol-
ving aberrant cellular metal trafficking are intricately
linked at the molecular level.
We reported biometal elevation in the brains of 2
CLN6 affected sheep models post-clinical onset [14], and
in the brains and heart of presymptomatic Cln6 mice [15].
Here we show significantly increased concentrations of
Cu and Zn in the brains of Merino CLN6 affected sheep
prior to clinical onset. While the spatio-temporal pattern
of metal concentrations is variable in tissues, this is not
unexpected for several reasons. As reported for Cln6 mice,
each brain and peripheral tissue region has different loca-
lized metal levels, which can vary across disease course
[15]. For instance, the stabilization in the levels of Cu in
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Figure 6 Delivery of bioavailable Zn restores Zn-dependent phenotypes through upregulation of Zip7. (A) Labile Zn in control (black
bars throughout) and Cln6 (white bars throughout) cortical neurons after 1 h ZnII(atsm) treatment was measured by FluoZin-3 fluorescence (N = 3). (B)
MT1A mRNA expression after 1 h ZnII(atsm) treatment in cortical neurons was assessed using qRT-PCR (N = 3). (C) Neurite length in control and Cln6
primary cortical neurons treated for 1 h with ZnII(atsm) was determined by tubulin immunofluorescence. Images (>1,000 cells/well from 4 experiments)
were taken using the ArrayScan High Content Platform and analysis was performed using Neuronal Profiling software (refer to Additional file 1).
(D) ALP activity in control and Cln6 primary mouse astrocytes was determined after 1 h ZnII(atsm) treatment (N = 3). (E) ZnII(atsm)-dependent
regulation of P-GSK and Zip7 levels after 4 h treatment was assessed in primary mouse astrocytes by western blotting. Images are from different
lanes on the same gel. (F-G) Normalized Zip7 protein levels in Merino sheep occipital lobe were plotted against normalized levels of Zn (F) and
P-GSK (G) to determine correlations between these proteins (N = 3 sheep per genotype). Linear regression analysis was performed in GraphPad
Prism. (H-J) Zip7 knockdown results in hyperphosphorylation of GSK3. 100nM negative control siRNA (−) or Zip7 siRNA (+) was transfected into
mouse NIH 3T3 cells. Zip7 (H) and P-GSK3 (I) protein expression was determined by Western blotting and normalized to expression of GAPDH.
Data are expressed as mean + SEM values. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test. (J) Images are representative of 3
independent experiments.
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lysosomal function (Figure 1A). This improvement could
represent the temporary efficacy of endogenous com-
pensatory mechanisms such as increased MT expression
(Figure 2F) that ultimately fail due to presence of per-
sistent stressors, causing animals to succumb to disease
by 14 months of age when metal concentrations rise as
reported [14]. Moreover, homeostasis of multiple bio-
metals is highly inter-related, and changes in one metal
can greatly affect the absorption or trafficking of others
in a cell- and tissue-specific manner [58]. It is also im-
portant to recognize that, as physiological control of
biometal homeostasis is so precise, even subtle focalmislocalisation of biometals can have a critical impact
on cell functions, as evident in Alzheimer’s disease. Al-
though it is now widely recognized that excess extracel-
lular Zn and Cu can promote amyloid β aggregation
[59] and studies suggest that intracellular metal levels
are depleted in Alzheimer’s disease [60], these changes
are rarely reflected in studies examining metal levels in
bulk tissue homogenates [61]. Similarly, the subtly al-
tered metal concentrations here, while indicative of glo-
bal metal dyshomeostasis, are insufficient to completely
capture the impaired subcellular biometal trafficking
dynamics. This is further supported by the significant
accumulation of Zn in 3 month-old brains detected in
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lysis. The substantial increase in MT expression (Figure 2F),
consistent with a recent report on MT overexpression in
LSDs [62], is likely a response to subcellular accumulation
of Zn and/or Cu in affected brain regions, but overex-
pressed cytoplasmic MT may not have direct access to ef-
fectively sequester mislocalized metal ions. Together these
results implicate widespread loss of biometal homeostasis
as an early disease feature.
Region-specific early alterations to the CLN6-colocalizing
metal transporter, Zip7, in multiple CLN6 disease models
indicate an important role of this metal transporter in
CLN6 NCL. Visual dysfunction in CLN6 NCL may also
be related to Zip7 expression changes, as Zip7 plays a
role in brain and eye development in zebrafish [63]. In-
deed, Zip7 loss in zebrafish caused eye defects [63], po-
tentially a phenocopy of CLN6 disease. Moreover, loss
of the Drosophila Zip7 homologue, Catsup, was recently
implicated in amyloid-precursor like protein accumula-
tion [64], providing additional links to Zip7 involvement
in neurodegeneration. Analysis of interactions between
Zip7 and different mutant forms of CLN6 may shed
light on the differences in cellular Zip7 concentrations
between mouse and sheep CLN6 models.
Due to high affinity interactions with proteins (as pre-
dicted by the Irwing-Williams series), the labile cellular
Zn content is estimated to be in the high picomolar
range [65], while ER and Golgi labile Zn concentrations
are kept at a subpicomolar range [66]. Increased com-
partmentalized labile Zn as a result of Zip7 loss may give
rise to consequential perturbations in the metabolism of
other metals. For instance, excess labile Zn may displace
redox-active transition metals from metalloproteins,
which may participate in Fenton-type ROS-producing
reactions. Additionally excess free Zn in the ER or Golgi
may aberrantly bind to, and inhibit, proteins. For in-
stance, Zn has been shown to inhibit protein tyrosine
phosphatases in the ER at low picomolar concentrations
[67]. Moreover, Zip7 loss may preclude kinase-dependent
Zn mobilization, termed “Zn wave” signals from being
propagated throughout cells [68], which may impact pleio-
tropic cellular signaling processes.
Further highlighting the role of Zip7 in CLN6 disease,
the metal complex, ZnII(atsm), restored Zn-dependent
functions and induced Zip7 upregulation and GSK3 de-
phosphorylation in primary Cln6 cells. As ZnII(atsm) is
membrane-permeable, delivery of Zn to intracellular com-
partments may bypass impaired cellular Zn trafficking
pathways. Labile Zn accumulation in primary Cln6 neu-
rons may be restricted to specific subcellular compart-
ments, as previously reported for Cln6 mouse brains [15],
and may therefore not stimulate MT upregulation prior
to addition of ZnII(atsm). Thus, ZnII(atsm) is likely to
exert protective effects via a dual mechanism involvingcombined induction of Zip7 and MT. Zip7 induced by
ZnII(atsm) may protect cells from toxic accumulation of
compartmentalized labile metals by transporting these
metals from the ER or Golgi, resulting in normalization
of subcellular metal levels. This would promote an in-
crease in bioavailable metals resulting in enhanced ac-
tivity of Zn-requiring enzymes such as ALP (Figure 6D).
Concomitantly, induction of MT is likely to result in
MT-dependent sequestration of any excess metals that are
liberated from the ER or Golgi in Cln6 cells that are not
directly required for enzymatic functions.Conclusions
Impaired metal homeostasis is a key hallmark of neuro-
degenerative disease. Here we show that aberrant biome-
tal functions in CLN6 disease are driven by loss of the
metal transporter, Zip7. The protective and metal modu-
lating effects of ZnII(atsm) treatment in vitro, coupled
with the proven success of metal btsc compounds in im-
proving motor and cognitive functions in neurodegener-
ation models in vivo [37-39], suggest that ZnII(atsm)
may be a candidate for NCL therapeutic trials.Additional files
Additional file 1: ZnII(atsm) treatment reduces aberrant neurite
branching in primary Cln6 cortical neurons. (A) Neurite branching in
control (black bars) and Cln6 (white bars) primary cortical neurons treated
for 1 h with ZnII(atsm) was determined by tubulin immunofluorescence.
(B) Representative image of tubulin staining of primary cortical neurons.
Images (>1,000 cells/well) were taken using the ArrayScan High Content
Platform. (C) Analysis was performed using Neuronal Profiling software.
Processed images show nuclei (blue), cell bodies (cyan), neurites (green
or magenta for neurites from neighboring neurons for easier
identification), branch points (yellow).
Additional file 2: Manganese and cobalt concentrations in the
tissues of preclinical CLN6 Merino sheep.
Additional file 3: Zip7 concentrations are significantly and
progressively reduced in CLN6 sheep. Immunoblots of homogenates
(5 μg) isolated from the occipital lobe of 3 and 14 month-old control (C)
or CLN6 affected sheep (N = 3-4 per group) probed with antibodies
directed against Zip7. Total ERK was used as a loading control.
Additional file 4: Unaltered metal transporter proteins in Merino
CLN6 affected sheep. (A-C) Densitometry and representative
immunoblots of homogenates (5–40 μg) isolated from the occipital lobe
of 3, 7 and 14 month old control or CLN6 affected Merino sheep (N = 3
per group) probed with antibodies directed against ZnT1 (A), ZnT3 (B) or
ZnT6 (C). GAPDH, β-tubulin, total Akt or total ERK, as appropriate, were
used as loading controls. Quantification was performed in ImageJ and
metal transporter levels are expressed relative to those in control sheep
at each age. C, control.
Additional file 5: Alterations to metal transporter protein
concentrations in South Hampshire CLN6 affected sheep. Densitometry
of western blots of homogenates (5–40 μg) isolated from the occipital lobe
12–14 month old control or CLN6 affected South Hampshire sheep or CLN5
heterozygote Borderdale sheep probed with antibodies directed against a
range of metal transporters. GAPDH was used as a loading control.
Quantification was performed in ImageJ and metal transporter levels are
expressed relative to those in control sheep at each age. * p < 0.05, ** p< 0.01
by Student’s t test. C, control; H, heterozygote; A, affected.
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http://www.actaneurocomms.org/content/2/1/25Additional file 6: Zip7 loss is region specific in Merino CLN6
affected sheep. Densitometry analyses and representative western blots
of Zip7 levels in the frontal lobe (A), parietal lobe (B) thalamus (C),
cerebellum (D), brainstem (E), liver (F) and muscle (G) of 3, 7, and
14-month-old control and CLN6 Merino sheep. GAPDH was used as a
loading control. Quantitation was performed in ImageJ and metal
transporter concentrations are expressed relative to those in control sheep
at each age. ** p < 0.01, *** p < 0.001 by Student’s t test.
Additional file 7: Zip7 loss is region specific South Hampshire CLN6
affected sheep. Densitometry of Zip7 western blots in the frontal lobe
(A), thalamus (B), cerebellum (C), brainstem (D) in 12–14 month old
control or CLN6 affected South Hampshire sheep (N = 3 per group) or
CLN5 heterozygote Borderdale sheep (N = 2). GAPDH was used as a
loading control. Quantification was performed in ImageJ and metal
transporter concentrations are expressed relative to those in control
sheep at each age. * p < 0.05, ** p < 0.01 by Student’s t test. C, control; H,
heterozygote; A, affected.
Additional file 8: Zip7 co-localizes with ER in primary cortical
neurons. Primary mouse cortical neurons were fixed and stained with
goat primary anti-Zip7 and rabbit primary anti-calnexin antibodies.
Anti-rabbit AlexaFluor-568 and anti-goat AlexaFluor 488 dye labeled
secondary antibodies were used to reveal Zip7 and calnexin expression.
Nuclei were stained with DAPI. (A) DAPI, (B) Zip7 and (C) calnexin expression
in primary cortical neurons was visualized by confocal microscopy using the
Zeiss Meta confocal scanning laser microscope using a magnification of
20×. (D) Overlay images. Scale bars correspond to 20 μm.
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